Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: Clinical outcomes of the Phase III intergroup trial alliance/CALGB 50303
Nancy L. Bartlett, Wyndham H. Wilson, Sin Ho Jung, Eric D. Hsi, Matthew J. Maurer, Levi D. Pederson, Mei Yin C. Polley, Brandelyn N. Pitcher, Bruce D. Cheson, Brad S. Kahl, Jonathan W. Friedberg, Louis M. Staudt, Nina D. Wagner-Johnston, Kristie A. Blum, Jeremy S. Abramson, Nishitha M. Reddy, Jane N. Winter, Julie E. Chang, Ajay K. Gopal, Amy ChadburnSusan Mathew, Richard I. Fisher, Kristy L. Richards, Heiko Schoder, Andrew D. Zelenetz, John P. Leonard
Dive into the research topics of 'Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: Clinical outcomes of the Phase III intergroup trial alliance/CALGB 50303'. Together they form a unique fingerprint.